gene therapy – it's in our DNA

Here you can find an overview, information and news related to investor relations at AveXis, Inc. You will find links to view AveXis’ financial reports, including our latest performance report, annual reviews, and financial reports. These reports will help you to better understand AveXis from both a financial and…

Read More

Dallas – June 24, 2014 – AveXis, Inc., a synthetic biology platform company, today announced that the first patient in the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now been enrolled and dosed by Nationwide Children’s Hospital. This trial utilizes chariSMA™, the gene therapy…

Read More

The Phase 1 gene transfer clinical trial using chariSMA™ in SMA Type 1 infants at Nationwide Children’s Hospital is now open for recruitment. For more information, please visit clinicaltrials.gov (NCT02122952). Nationwide Children’s Hospital received IND approval and Fast Track designation from the FDA in…

Read More

AveXis is dedicated to supporting families who are affected by Spinal Muscular Atrophy. We are proud sponsors of organizations like Cure SMA, The Sophia’s Cure Foundation, and Avery’s Race who are trying to spread awareness and support to communities so that we can find a treatment for SMA.

Read More